Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Shockwave Medical Inc

Healthcare US SWAV

NoneUSD
0.00(0%)

Last update at 2024-06-26T21:04:05.590268Z

Day Range

--
LowHigh

52 Week Range

157.00334.75
LowHigh

Fundamentals

  • Previous Close 334.75
  • Market Cap12560.18M
  • VolumeNone
  • P/E Ratio78.72
  • Dividend Yield-%
  • EBITDA180.34M
  • Revenue TTM787.97M
  • Revenue Per Share TTM21.34
  • Gross Profit TTM 424.74M
  • Diluted EPS TTM4.25

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 120.83M -8.83500M -65.61900M -51.04700M -41.06400M
Minority interest - - - - -
Net income 216.00M -9.13600M -65.69900M -51.10900M -41.10200M
Selling general administrative 56.93M 34.75M 23.86M 14.13M 5.98M
Selling and marketing expenses 162.00M 111.29M 51.67M 30.62M 17.54M
Gross profit 424.74M 195.71M 46.80M 25.77M 5.01M
Reconciled depreciation 4.86M 5.54M 3.35M 2.28M 0.70M
Ebit 124.13M -0.87100M -65.66300M -51.83900M -40.61100M
Ebitda 122.71M -7.73900M -64.40700M -49.49400M -39.91100M
Depreciation and amortization -1.42000M -6.86800M 1.26M 2.35M 0.70M
Non operating income net other - -6.86800M 1.26M - -
Operating income 124.13M -0.87100M -65.66300M -51.83900M -41.20000M
Other operating expenses 365.60M 238.02M 133.45M 94.77M 53.46M
Interest expense 1.89M 1.10M 1.21M 0.94M 0.40M
Tax provision -95.16800M 0.30M 0.08M 0.06M 0.04M
Interest income - - - 0.94M 0.40M
Net interest income -1.88600M -1.09600M -1.21200M -0.94400M -0.40100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -95.16800M 0.30M 0.08M 0.06M 0.04M
Total revenue 489.73M 237.15M 67.79M 42.93M 12.26M
Total operating expenses 300.60M 196.58M 112.46M 77.61M 46.21M
Cost of revenue 65.00M 41.44M 20.99M 17.16M 7.25M
Total other income expense net -3.30600M -7.96400M 0.04M 0.79M 0.54M
Discontinued operations - - - - -
Net income from continuing ops 216.00M -9.13600M -65.69900M -51.10900M -41.10200M
Net income applicable to common shares 216.00M -9.13600M -65.69900M -51.10900M -41.10200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1566.56M 646.09M 345.68M 272.04M 231.94M
Intangible assets 92.86M - - - -
Earning assets - - - - -
Other current assets 12.57M 8.29M 4.51M 2.40M 1.90M
Total liab 897.89M 134.77M 103.85M 46.39M 39.28M
Total stockholder equity 668.68M 511.32M 241.83M 225.65M 192.65M
Deferred long term liab - - - - -
Other current liab 91.70M 55.38M 40.87M 19.94M 13.78M
Common stock 0.04M 0.04M 0.04M 0.04M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.03M
Retained earnings 110.47M -36.81300M -252.80900M -243.67300M -177.97400M
Other liab - 12.27M 12.27M - -
Good will 39.57M - - - -
Other assets - 102.80M 1.94M 9.38M 1.51M
Cash 328.42M 156.59M 89.21M 50.42M 139.04M
Cash and equivalents - - - - -
Total current liabilities 104.20M 63.37M 51.63M 25.58M 24.01M
Current deferred revenue - - - - -
Net debt 442.19M -96.18200M -42.02000M -25.44300M -116.32700M
Short term debt 3.64M 1.28M 7.24M 4.17M 7.44M
Short long term debt - - 5.50M 3.30M 6.67M
Short long term debt total 770.61M 60.40M 47.19M 24.98M 22.72M
Other stockholder equity 557.88M 548.96M 494.81M 469.28M 138.62M
Property plant equipment - 80.52M 51.86M 16.36M 13.73M
Total current assets 1225.26M 459.26M 285.90M 246.30M 216.70M
Long term investments 1.64M 3.51M 5.99M - -
Net tangible assets - 511.32M 241.83M 225.65M 192.65M
Short term investments 662.13M 147.91M 111.77M 151.93M 56.30M
Net receivables 114.55M 71.37M 37.44M 11.69M 7.38M
Long term debt 731.86M 24.20M 11.63M 13.32M 7.15M
Inventory 107.59M 75.11M 42.98M 29.86M 12.07M
Accounts payable 8.87M 6.72M 3.52M 1.47M 2.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.29M -0.86700M -0.20200M 0.00900M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - 0.04M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - -252.80900M -243.67300M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 8.03M 5.23M 1.94M 1.81M 1.51M
Deferred long term asset charges - - - - -
Non current assets total 341.30M 186.83M 59.78M 25.74M 15.24M
Capital lease obligations 38.74M 36.21M 30.06M 8.36M 8.90M
Long term debt total - - 11.63M 13.32M 7.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -62.15000M 38.85M -95.95300M -59.54300M 1.81M
Change to liabilities 1.95M 23.51M 2.62M 1.27M 0.36M
Total cashflows from investing activities -62.15000M 26.42M -107.47300M -59.54300M -0.17400M
Net borrowings 5.97M 5.97M 3.27M -1.66700M 14.99M
Total cash from financing activities 13.00M -2.45100M 90.03M 208.05M 29.81M
Change to operating activities 3.15M 19.43M 2.45M 6.58M 1.81M
Net income 216.00M -9.13600M -65.69900M -51.10900M -41.10200M
Change in cash 67.43M 39.00M -88.62200M 100.40M -11.83000M
Begin period cash flow 90.87M 51.87M 140.50M 40.09M 51.92M
End period cash flow 158.30M 90.87M 51.87M 140.50M 40.09M
Total cash from operating activities 117.73M 15.04M -71.18400M -48.10700M -41.46500M
Issuance of capital stock 0.00000M 0.00000M 83.37M 207.40M 14.92M
Depreciation 4.86M 5.54M 3.35M 2.28M 0.70M
Other cashflows from investing activities - - - -55.72600M 1.81M
Dividends paid - - -1.79500M - -
Change to inventory -29.71100M -12.07300M -17.05600M -6.82400M -2.60800M
Change to account receivables -33.31300M -25.74600M -4.31200M -4.52700M -2.21100M
Sale purchase of stock 4.49M 5.89M 1.79M 199.72M 15.45M
Other cashflows from financing activities 26.71M -2.45100M 7.78M 2.32M 29.81M
Change to netincome -45.72200M 33.55M 10.54M 3.78M 1.38M
Capital expenditures 25.13M 12.44M 11.52M 3.82M 1.98M
Change receivables - -25.74600M -4.31200M - -
Cash flows other operating - -0.24900M -0.08800M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 39.00M -88.62200M - -
Change in working capital -57.93100M -16.51800M -20.31400M -3.49400M -2.64900M
Stock based compensation 44.89M 27.26M 10.35M 3.65M 1.30M
Other non cash items 7.20M 0.51M 0.65M 0.44M 0.21M
Free cash flow 92.61M 2.60M -82.70400M -51.92400M -43.44600M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SWAV
Shockwave Medical Inc		 - -% - 78.72 68.49 16.83 18.38 16.53 63.03
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Shockwave Medical Inc

5403 Betsy Ross Drive, Santa Clara, CA, United States, 95054

Key Executives

Name Title Year Born
Mr. Douglas E. Godshall M.B.A. Pres, CEO & Director 1965
Mr. Daniel Puckett MBA CFO, Principal Financial Officer & Sec. 1964
Mr. Isaac Zacharias Chief Commercial Officer 1975
Mr. Daniel Hawkins Founder and Sr. Advisor 1967
Mr. John M. Adams Co-Founder and Technical Advisor 1947
Mr. Mike Maszy VP of Operations NA
Ms. Trinh Phung Chief Accounting Officer, Principal Accounting Officer & VP of Fin. 1978
Ms. Debbie Kaster VP of Investor Relations NA
Mr. Hajime Tada J.D. Gen. Counsel & Sec. NA
Mr. Rob Williamson Jr. VP of Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions